Damora Therapeutics, Inc. (DMRA)
NASDAQ: DMRA · Real-Time Price · USD
31.80
+0.71 (2.28%)
At close: Aug 18, 2026, 4:00 PM EDT
31.80
0.00 (0.00%)
After-hours: Aug 18, 2026, 4:01 PM EDT
Damora Therapeutics Stock Forecast
Stock Price Forecast
According to 10 analysts polled by S&P Global, Damora Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $44.67. The average 1-year stock price forecast is 40.47% higher than the current stock price, while the lowest is $40 (+25.79%) and the highest is $51 (+60.38%).
Price Target: $44.67 (+40.47%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Damora Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 6 | 8 | 9 | 9 |
| Buy | 0 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 7 | 9 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Buy Maintains $50 | Buy | Maintains | $50 | +57.23% | Aug 11, 2026 |
| Wedbush | Wedbush | Buy Maintains $40 | Buy | Maintains | $40 | +25.79% | Aug 11, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $40 | Buy | Maintains | $40 | +25.79% | Aug 11, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Maintains $45 | Buy | Maintains | $45 | +41.51% | Aug 11, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $45 | Buy | Reiterates | $45 | +41.51% | Aug 11, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.89
EPS Next Year
-2.14
from -1.89
EPS and Forward PE are based on non-GAAP adjusted numbers.